$40/share by the end of the year seems about right

Would you please give a prediction of their stock price.

Very true, but if that's the case they need to lean-out operations to show profitability on just the life sci biz. No reason they shouldn't have been running in the black for the past 2 years.
Inexperienced CEO has no true operations experience. BJ/RR care only for themselves. MU/AB have been truly brilliant at creating a toxic culture.
All should move aside and let the grownups make the company a real success before time renders them irrelevant.

Leave these guys alone. They made it onto the NASDAQ. It took a long time but it looks like they have a viable business based on microfluidic arrays. Diagnostics may be possible in the long run too but even if not, they now have a decent biz in life science tools.

there is a market for cattle and fish diagnostics

Diagnostic field? LMAO. VC will need to schedule a 2nd offering.

Compared to any other microfluidic company, Fluidigm is the only one having enabling technologies. Sure it is not perfect but no technology is, otherwise we’d stop bringing news ones to the market. Their Digital array is truly unique, it allows to gain information that would not be accessible with current systems. It has a fantastic potential in the diagnostic field, MRSA detection is basically straight forward. Can’t wait to read more on the topic.

Money should do the trick!

Only a miracle can save this company now.

Really? They just ramped up the sales force. who left, what regions?

Fluidigm just secured another 8.8 million in financing: (HTTP://online.wsj.com/article/BT-CO-20110113-716069.html)
What is the significance of this in light of their presumably imminent IPO?

Losing sales reps at record pace. At least overheard will be low!

Our analysts predict the CEO will cut and run after the IPO. The initial price will be substantially lower than expected and result in management and head count reductions.

CEO predicts breaking even mid 2011!

Has Filed S1 again, nice increase in sales over the last couple of year but not yet profitable, but getting closer ...

No short term gains by acquiring this company or its technology. It is a long shot. The company is still in debt after 10 years as sales just trickle in. Investors should look elsewhere to find a better deal. Management should revamp sales and marketing before the competition closes in and the lights go out.

please merge with a benevolent company

We did a survey including them and the responses were nearly all positive

how do you know their customers are satisfied?

What I don't understand is why they aren't for sale yet. They missed ipo, valuations are down, and their management team is weak. The core technology is still impressive, they can manufacture ( with a few bumps- normal for any company of this size) and they make good products- their customers are satisfied. they would benefit for better sales and marketing, and they are still struggling as a standalone company.
At most they must be worth $150-200m ( even if you believe their revenue projections from the aborted ipo, which seem unlikely at this point). At this price , they look like a good buy for any of the bigger players out there. Qiagen, millipore, thermo, GE, illumina, life. Seems
Obvious. Why hasn't anyone jumped in?

People love to kick this company because it is a archetypal example of what happens when you put good technology in incompetent hands. The use of microfluidics is exploding. Fluidigm was one of the first companies in the space, (Caliper was certainly ahead of them, but they were probably the only ones with a significant lead) and the soft microfluidics gave Fluidigm a sustainable competitive advantage. The only problem was the advantage wasn't sustained due to a simultaneous fear of lawsuits from established companies and an egotism about superior technology being the only thing that mattered. Wrong on both counts. Bottom line - bad management.

Why do so many like to kick this company? They do deserve a lot of critical review but so do many others.

Is it the amount of money invested so far verses returns or is it just a perfect poster child for the kind of resource wasting games we saw so much of for the past 10 years?

Will Fluidigm follow the lead of Pacbio? Will we see all a new round of IPOs. It is about time to leverage all these PR expenses over the years.

Circling the drain as competition closes in. New and useful products will be essential for their survival. time is running out.